Martha Neagu
Senior Medical Director, Clinical Development Oncology Abbvie
Martha is a physician scientist and clinical investigator with expertise in oncology drug development. Her principal interest is in developing tumor targeting therapies including antibody drug conjugates for patients with advanced cancer.
Martha obtained her MD/PhD degrees at Columbia University and continued her clinical training in Neurology at Harvard Medical School (HMS). During her internal medicine training, she became interested in oncology and pursued additional fellowship training in Neuro-Oncology. As HMS junior faculty, Martha’s research focused novel immunotherapy targets for the treatment of glioblastoma and she established a neuro-oncology department at the Boston Veteran’s Affairs Hospital.
She joined AbbVie in 2018 where she completed the Physician Development Program after which she joined the oncology early development group and followed Telisotuzumab Adizutecan as a senior medical director in the All Oncology Development Group.
Seminars
- Understanding the challenges of ADC development in an increasingly crowded clinical environment
- Evaluating opportunities to demonstrate differentiation across ADC trial design, patient selection, and combination approaches
- Debating the opportunities to improve ADC clinical execution to reduce development costs and improve ADC clinical trial
- Laying out the history and progress made developing ADCs and other therapeutics against c-Met
- Detailing the safety and efficacy profile of ABBV-400 across lung, CRC and solid tumour indications
- Exploring lessons learned to optimise ABBV-400 clinical profile and evaluating the concept of ADCs as targeted therapies
